Results 301 to 310 of about 232,884 (341)
Adipose Composition Before and After Primary Aldosteronism Treatment Depends on Primary Aldosteronism Subtypes and Plasma Aldosterone Concentration Before the Treatment. [PDF]
Nakano E+5 more
europepmc +1 more source
Cardiovascular Health in Women—Across the Lifespan
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar+5 more
wiley +1 more source
Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19. [PDF]
Wu B+7 more
europepmc +1 more source
ABSTRACT Objective Successful adrenal venous sampling (AVS) is traditionally assessed using the ratio of cortisol in adrenal to peripheral venous plasma to calculate the selectivity index. With mass spectrometry other steroids can be simultaneously measured that may improve numbers of apparent successful sampling procedures.
Francesco Alessi+14 more
wiley +1 more source
Renal cell carcinoma accompanied by aldosterone-secreting contralateral adrenal metastasis: a case report. [PDF]
Doyya M, Alloush G, Alloush M.
europepmc +1 more source
Abstract Aims This study investigates the impact of the era of diabetes onset on the prevalence of diabetic retinopathy and albuminuria 15 years post‐diagnosis in people living with type 1 diabetes (T1D) within a national healthcare system offering structured multidisciplinary endocrinology care.
Astrid Lavens+8 more
wiley +1 more source
Superselective Adrenal Artery Embolization as a Novel Alternative Treatment for Aldosterone-Producing Adenomas: A Case of Refractory Hypertension With Concomitant Autonomous Cortisol Secretion. [PDF]
Xu Z+5 more
europepmc +1 more source
Abstract Aims In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real‐world settings.
Kim G. Smolderen+10 more
wiley +1 more source